Výsledky vyhledávání - "Amy Bartalotta"

Akademický článek

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Autor: Mônica Gadelha, Marie Bex, Annamaria Colao, Elier Mitsael Pedroza García, Catalina Poiana, Marisela Jimenez-Sanchez, Serkan Yener, Rishav Mukherjee, Amy Bartalotta, Ricardo Maamari, Gérald Raverot

Publikováno v: Frontiers in Endocrinology, Vol 10 (2020)

Introduction: Acromegaly is a rare, serious endocrine disorder characterized by excess growth hormone (GH) secretion by a pituitary adenoma and overproduction of insulin-like growth factor I (IGF-I). Transsphenoidal surgery is the treatment of choice

Externí odkaz: https://doaj.org/article/7eae9d3ca3464285ae2d01cf9405f65e

Zobrazit plný text záznamu

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial

Publikováno v: The Lancet Oncology, 22(12), 1752-1763. Lancet Publishing Group

Summary Background The primary analysis of the phase 3 NETTER-1 trial showed significant improvement in progression-free survival with 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide alone in patients with advanced

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0058dd366f1b523fe4859adad415c3
https://doi.org/10.1016/s1470-2045(21)00572-6

Zobrazit plný text záznamu

O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs

Autor: Jonathan R. Strosberg, Ettore Seregni, Sakir Mutevelic, Pamela L. Kunz, Martyn Caplin, E.P. Krenning, Lisa Bodei, Amy Bartalotta, Arnaud Demange, Hugo Duarte, Marianne Pavel, Philippe Ruszniewski, Edward M. Wolin, Erik Mittra, E. Grande Pulido, E. Van Cutsem, James C. Yao, Andrew Eugene Hendifar, Germo Gericke

Publikováno v: Annals of Oncology. 32:S217-S218

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0a161e7b3d222b746a736a9de30c7adc
https://doi.org/10.1016/j.annonc.2021.05.006

Zobrazit plný text záznamu

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Autor: Amy Bartalotta, Catalina Poiana, Mônica R. Gadelha, Marisela Jiménez-Sánchez, Serkan Yener, Gérald Raverot, Marie Bex, Rishav Mukherjee, Elier Mitsael Pedroza García, Annamaria Colao, Ricardo Maamari

Publikováno v: Frontiers in Endocrinology
Frontiers in Endocrinology, Vol 10 (2020)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a70393b3e5f4f14ae2f942f379922b4f
http://europepmc.org/articles/PMC7008501

Zobrazit plný text záznamu

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study

Autor: Federico Campigotto, Marie Bex, Mônica R. Gadelha, Amy Bartalotta, Ricardo Maamari, Annamaria Colao, Gérald Raverot

Publikováno v: Journal of the Endocrine Society

Background: In a 24-week, Phase 3 study (PAOLA), long-acting pasireotide demonstrated superior efficacy (GH 1.3xULN) despite ≥3 months of treatment with maximal approved doses of long-acting octreotide/lanreotide received open-label long-acting pas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48585ae0fae6f1af1ebededf907b72fe
https://doi.org/10.1210/js.2019-sat-433

Zobrazit plný text záznamu

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors

Autor: Eric P. Krenning, Arnaud Demange, Amy Bartalotta, Lisa Bodei, Sakir Mutevelic, Germo Gericke, Marianne Pavel, Erik Mittra, James C. Yao, Eric Van Cutsem, Pamela L. Kunz, Philippe Ruszniewski, Ettore Seregni, Enrique Grande, Jonathan R. Strosberg, Edward M. Wolin, Martyn Caplin, Hugo Duarte, Andrew Eugene Hendifar

Publikováno v: Journal of Clinical Oncology. 39:4112-4112

4112 Background: As demonstrated in the primary analysis of the phase 3 NETTER-1 trial, 177Lu-DOTATATE significantly prolonged progression-free survival (PFS) versus high-dose long-acting octreotide, with a HR of 0.18 (95% CI: 0.11, 0.29; p < 0.0001)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::426a3189822a2a68b69353c92f620eb5
https://doi.org/10.1200/jco.2021.39.15_suppl.4112

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání